+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Drugs In Development, 2021

  • PDF Icon

    Report

  • 154 Pages
  • August 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5438173
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3. 5.1. 98) - Histone deacetylase 6 is an enzyme encoded by the HDAC6 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. It is involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. It plays a key role in the degradation of misfolded proteins. It acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy.

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3. 5.1. 98) pipeline Target constitutes close to 51 molecules. Out of which approximately 42 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 4, 1, 27 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.

The report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Immunology, Toxicology, Infectious Disease, Undisclosed, Cardiovascular, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Musculoskeletal Disorders and Respiratory which include indications Multiple Myeloma (Kahler Disease), Melanoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Breast Cancer, Charcot-Marie-Tooth Disease Type II, Solid Tumor, Charcot-Marie-Tooth Disease, Chemotherapy Induced Peripheral Neuropathy, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Multiple Sclerosis, Non-Small Cell Lung Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Triple-Negative Breast Cancer (TNBC), Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Leukemia, Mantle Cell Lymphoma, Ovarian Cancer, Pancreatic Cancer, Rheumatoid Arthritis, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Unspecified, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenoid Cystic Carcinoma (ACC), Amyotrophic Lateral Sclerosis, Anal Cancer, Autoimmune Disorders, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Burkitt Lymphoma, Cervical Cancer, Chronic Kidney Disease (Chronic Renal Failure), CNS Lymphoma, Coronavirus Disease 2019 (COVID-19) Pneumonia, Crohn's Disease (Regional Enteritis), Cutaneous T-Cell Lymphoma, Diabetic Neuropathic Pain, Diabetic Peripheral Neuropathy, Diastolic Heart Failure, Dilated Cardiomyopathy, Distal Symmetric Polyneuropathy, Fibrosis, Gastric Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Human Papillomavirus (HPV) Associated Cancer, Huntington Disease, Idiopathic Pulmonary Fibrosis, Liver Cancer, Lung Adenocarcinoma, Lupus Nephritis, Lymphoma, Marginal Zone B-cell Lymphoma, Mycosis Fungoides, Myelodysplastic Syndrome, Myeloproliferative Disorders, Neuroblastoma, Neurology, Neuropathic Pain (Neuralgia), Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Polycystic Kidney Disease, Prostate Cancer, Rectal Cancer, Recurrent Medulloblastoma, Rett Syndrome, Sepsis, Small-Cell Lung Cancer, Systemic Sclerosis (Scleroderma), Tauopathies, Ulcerative Colitis, Unspecified B-Cell Lymphomas and Vulvar Cancer.

The latest report Histone Deacetylase 6 - Drugs In Development, 2021, outlays comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3. 5.1. 98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3. 5.1. 98) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3. 5.1. 98)
  • The report reviews Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3. 5.1. 98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3. 5.1. 98) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3. 5.1. 98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3. 5.1. 98) targeted therapeutics

Reasons to Buy


  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3. 5.1. 98)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3. 5.1. 98) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

IntroductionHistone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - OverviewHistone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics DevelopmentHistone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics AssessmentHistone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Drug Profiles
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Dormant Products

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Product Development MilestonesAppendix
List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indications, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Annji Pharmaceutical Co Ltd, 2021
  • Pipeline by ATP Biopharm, 2021
  • Pipeline by Augustine Therapeutics, 2021
  • Pipeline by Beijing Konruns Pharmaceutical Co Ltd, 2021
  • Pipeline by Bristol Myers Squibb Co, 2021
  • Pipeline by Chong Kun Dang Pharmaceutical Corp, 2021
  • Pipeline by Convalife, 2021
  • Pipeline by CStone Pharmaceuticals Co Ltd, 2021
  • Pipeline by Curis Inc, 2021
  • Pipeline by Eikonizo Therapeutics Inc, 2021
  • Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, 2021
  • Pipeline by Hillstream BioPharma Inc, 2021
  • Pipeline by Jubilant Therapeutics Inc, 2021
  • Pipeline by Kancera AB, 2021
  • Pipeline by Karus Therapeutics Ltd, 2021
  • Pipeline by KYAN Therapeutics Inc, 2021
  • Pipeline by Medivir AB, 2021
  • Pipeline by Merck & Co Inc, 2021
  • Pipeline by Mycovia Pharmaceuticals Inc, 2021
  • Pipeline by OnKure Inc, 2021
  • Pipeline by Oryzon Genomics SA, 2021
  • Pipeline by Quimatryx SL, 2021
  • Pipeline by Shuttle Pharmaceuticals Inc, 2021
  • Pipeline by SK Biopharmaceuticals Co Ltd, 2021
  • Pipeline by Starwise Therapeutics LLC, 2021
  • Pipeline by Tenaya Therapeutics Inc, 2021
  • Dormant Products, 2021

List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Annji Pharmaceutical Co Ltd
  • ATP Biopharm
  • Augustine Therapeutics
  • Beijing Konruns Pharmaceutical Co Ltd
  • Bristol Myers Squibb Co
  • Chong Kun Dang Pharmaceutical Corp
  • Convalife
  • CStone Pharmaceuticals Co Ltd
  • Curis Inc
  • Eikonizo Therapeutics Inc
  • Guangdong Zhongsheng Pharmaceutical Co Ltd
  • Hillstream BioPharma Inc
  • Jubilant Therapeutics Inc
  • Kancera AB
  • Karus Therapeutics Ltd
  • KYAN Therapeutics Inc
  • Medivir AB
  • Merck & Co Inc
  • Mycovia Pharmaceuticals Inc
  • OnKure Inc
  • Oryzon Genomics SA
  • Quimatryx SL
  • Shuttle Pharmaceuticals Inc
  • SK Biopharmaceuticals Co Ltd
  • Starwise Therapeutics LLC
  • Tenaya Therapeutics Inc